Yihai Cao is at the Department of Microbiology, Tumour and Cell Biology, Karolinska Institute, 171 77 Stockholm.
Nat Rev Drug Discov. 2010 Feb;9(2):107-15. doi: 10.1038/nrd3055.
Current pharmacotherapeutic options for treating obesity and related metabolic disorders remain limited and ineffective. Emerging evidence shows that modulators of angiogenesis affect the expansion and metabolism of fat mass by regulating the growth and remodelling of the adipose tissue vasculature. Pharmacological manipulation of adipose tissue neovascularization by angiogenic stimulators and inhibitors might therefore offer a novel therapeutic option for the treatment of obesity and related metabolic disorders. This Perspective discusses recent progress in understanding the molecular mechanisms that control adipose tissue angiogenesis and in defining potential new vascular targets and approaches for the treatment of this group of diseases.
目前治疗肥胖症和相关代谢紊乱的药物治疗选择仍然有限且效果不佳。新出现的证据表明,血管生成调节剂通过调节脂肪组织血管的生长和重塑来影响脂肪量的扩张和代谢。通过血管生成刺激剂和抑制剂对脂肪组织新生血管的药理学操纵因此可能为肥胖症和相关代谢紊乱的治疗提供一种新的治疗选择。本观点讨论了在理解控制脂肪组织血管生成的分子机制方面的最新进展,并确定了治疗这组疾病的潜在新血管靶点和方法。